Ascentage Pharma Group International (NASDAQ:AAPG) Upgraded by BTIG Research to Strong-Buy Rating

BTIG Research upgraded shares of Ascentage Pharma Group International (NASDAQ:AAPG) to a strong-buy rating in a research report report published on Wednesday morning,Zacks.com reports.

Several other research firms have also recently issued reports on AAPG. Truist Financial set a $51.00 price objective on Ascentage Pharma Group International in a research report on Monday, November 24th. Lucid Cap Mkts raised Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, December 15th. Oppenheimer initiated coverage on Ascentage Pharma Group International in a research note on Thursday, December 4th. They issued an “outperform” rating and a $45.00 price target for the company. Finally, Rodman & Renshaw assumed coverage on Ascentage Pharma Group International in a report on Tuesday, January 13th. They set a “buy” rating and a $48.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and five have issued a Buy rating to the company’s stock. According to MarketBeat.com, Ascentage Pharma Group International has an average rating of “Buy” and an average price target of $48.00.

Ascentage Pharma Group International Stock Performance

NASDAQ:AAPG opened at $24.43 on Wednesday. The company has a current ratio of 1.54, a quick ratio of 1.53 and a debt-to-equity ratio of 1.31. The company’s 50 day moving average price is $25.05 and its 200-day moving average price is $31.18. Ascentage Pharma Group International has a 52 week low of $17.56 and a 52 week high of $48.45.

Institutional Investors Weigh In On Ascentage Pharma Group International

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. UBS Group AG boosted its stake in shares of Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after buying an additional 10,988 shares during the last quarter. XY Capital Ltd increased its position in Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after acquiring an additional 12,530 shares during the last quarter. Tema Etfs LLC purchased a new stake in Ascentage Pharma Group International during the second quarter valued at $610,000. Hsbc Holdings PLC bought a new position in Ascentage Pharma Group International in the second quarter valued at about $391,000. Finally, Citadel Advisors LLC purchased a new position in Ascentage Pharma Group International in the third quarter worth about $383,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.